These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 28724177)

  • 1. Natural molecules for the therapy of hyperandrogenism and metabolic disorders in PCOS.
    Cappelli V; Musacchio MC; Bulfoni A; Morgante G; De Leo V
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(2 Suppl):15-29. PubMed ID: 28724177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
    Musacchio MC; Cappelli V; Di Sabatino A; Morgante G; De Leo V
    Minerva Ginecol; 2013 Feb; 65(1):89-97. PubMed ID: 23412023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic approach for metabolic disorders and infertility in women with PCOS.
    Morgante G; Massaro MG; Di Sabatino A; Cappelli V; De Leo V
    Gynecol Endocrinol; 2018 Jan; 34(1):4-9. PubMed ID: 28850273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal contraceptive choice for women with PCOS: a systematic review of randomized trials and observational studies.
    Mendoza N; Simoncini T; Genazzani AD
    Gynecol Endocrinol; 2014; 30(12):850-60. PubMed ID: 25254621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.
    Escobar-Morreale HF
    Nat Rev Endocrinol; 2018 May; 14(5):270-284. PubMed ID: 29569621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is foetal hyperexposure to androgens a cause of PCOS?
    Filippou P; Homburg R
    Hum Reprod Update; 2017 Jul; 23(4):421-432. PubMed ID: 28531286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herbal medicine for the management of polycystic ovary syndrome (PCOS) and associated oligo/amenorrhoea and hyperandrogenism; a review of the laboratory evidence for effects with corroborative clinical findings.
    Arentz S; Abbott JA; Smith CA; Bensoussan A
    BMC Complement Altern Med; 2014 Dec; 14():511. PubMed ID: 25524718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome.
    Banaszewska B; Pawelczyk L; Spaczynski R
    Reprod Biol; 2019 Dec; 19(4):309-315. PubMed ID: 31606349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
    Stracquadanio M; Ciotta L; Palumbo MA
    Gynecol Endocrinol; 2018 Jun; 34(6):495-501. PubMed ID: 29265900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
    De Leo V; Musacchio MC; Palermo V; Di Sabatino A; Morgante G; Petraglia F
    Drugs Today (Barc); 2009 Oct; 45(10):763-75. PubMed ID: 20069140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
    Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
    Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Syndrome: Polycystic Ovary Syndrome.
    Mortada R; Williams T
    FP Essent; 2015 Aug; 435():30-42. PubMed ID: 26280343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.
    Iervolino M; Lepore E; Forte G; Laganà AS; Buzzaccarini G; Unfer V
    Nutrients; 2021 May; 13(5):. PubMed ID: 34063339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which treatment options should be used in adolescents with polycystic ovary syndrome?
    Villa P; Di Sebastiano F; Rossodivita A; Sagnella F; Barini A; Fulghesu AM; Lanzone A
    J Pediatr Endocrinol Metab; 2004 May; 17(5):705-10. PubMed ID: 15237703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis.
    Naderpoor N; Shorakae S; de Courten B; Misso ML; Moran LJ; Teede HJ
    Hum Reprod Update; 2015; 21(5):560-74. PubMed ID: 26060208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of hyperandrogenism in female obesity and cardiometabolic diseases associated with polycystic ovary syndrome.
    Barber TM; Vojtechova P; Franks S
    Horm Mol Biol Clin Investig; 2013 Sep; 15(3):91-103. PubMed ID: 25436736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.